UnknownPhase 2NCT05077813

Utilizing the Crosstalk Among Chicoric Acid, 13-Cis Retinoic Acid(Aerosolized), Minocycline and Vitamin D as a Potent Quadrate Therapy for Treating Patients With Multidrug-resistant TB and Patient With Both Multidrug-resistant TB and COVID-19

Studying Tuberculosis

Last synced from ClinicalTrials.gov

Clinical trial records are synced from ClinicalTrials.gov through automated extraction.
Report missing data

Key facts

Sponsor
Kafrelsheikh University
Principal Investigator
Dr Mahmoud R Elkazzaz, M.Sc of Biochemistry
Faculty of Science , Damietta University
Intervention
13 cis retinoic acid, Minocycline, Chicroic Acid and Vitamin D for (MDR-TB)(combination_product)
Enrollment
250 enrolled
Eligibility
18-65 years · All sexes
Timeline
20212022

Study locations (2)

Collaborators

Ministry of Health, Saudi Arabia

Primary source

Recruitment status, site addresses, contacts, and full eligibility criteria can change between syncs. Always verify with the trial team before planning travel or treatment.

Open NCT05077813 on ClinicalTrials.gov

Other trials for Tuberculosis

Additional recruiting or active studies for the same condition.

See all trials for Tuberculosis

← Back to all trials